Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.
<p>Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.</p>
Guardat en:
| Autor principal: | Seyed Reza Mousavi (13223324) (author) |
|---|---|
| Altres autors: | Alihasan Rahmani (22676321) (author), Maryam Amini Pouya (22676324) (author), Elnaz Zabihi Eidgahi (22676327) (author), Mohamad Delirrad (22676330) (author), Hamed Hosseini (3480455) (author), Alireza Ghassemi Toussi (22676333) (author), Behnaz Hedayatjoo (22676336) (author), Seyyedeh Maryam Afshani (22676339) (author), Mohammad Amin Ghobadi (22676342) (author), Mohammad Reza Shahidi (22676345) (author), Seyed Amirhossein Mousavi (22676348) (author), Maryam Barghbani (22676351) (author), Mahdi Jannati Yazdan Abad (22676354) (author) |
| Publicat: |
2025
|
| Matèries: | |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
Ítems similars
-
Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].
per: Seyed Reza Mousavi (13223324)
Publicat: (2025) -
The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.
per: Seyed Reza Mousavi (13223324)
Publicat: (2025) -
Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.
per: Seyed Reza Mousavi (13223324)
Publicat: (2025) -
Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.
per: Seyed Reza Mousavi (13223324)
Publicat: (2025) -
Table 1_Immune responses in pulmonary sarcoidosis following COVID-19.docx
per: Anna Starshinova (22571846)
Publicat: (2025)